Ⅰ至Ⅲ期肺癌根治性治疗完成后氟-18氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描监测:SUPE_R随机对照试验
SUPE_R多中心随机对照试验将750例ⅠA至ⅢC期非小细胞肺癌根治性治疗后患者一比一随机分入[18F]FDG PET/CT组(n=373)或增强CT组(n=377)。两组复发接受根治性治疗的比例均为48%(PET组42/87,CT组37/77,p=0.98),TTR与OS无显著差异。结论不支持常规使用[18F]FDG PET/CT进行治疗后监测。
要点
- PET组与CT组复发接受根治性治疗比例均为48%(42/87 vs 37/77,p=0.98)。
- PET组经计划随访检出复发比例90%,高于CT组77%(p=0.02)。
- 两组TTR(HR 1.12,95%CI 0.82-1.52,p=0.48)与OS(HR 0.97,95%CI 0.66-1.43,p=0.89)无显著差异。
核心结论
- 在根治性治疗后的NSCLC患者中,与增强CT相比,[18F]FDG PET/CT监测未改善复发接受根治性治疗的比例、TTR或OS,这些发现不支持常规使用[18F]FDG PET/CT进行治疗后监测。
研究设计与样本
- 多中心随机对照试验(SUPE_R,ClinicalTrials.gov NCT03740126),ⅠA至ⅢC期NSCLC患者根治性治疗完成后一比一随机分入标准监测(增强CT)组或[18F]FDG PET/CT监测组。
- 2019年2月至2022年2月共随机750例,PET/CT组n=373,CT组n=377。
- 主要结局为复发接受根治性治疗的比例,次要结局包括至复发时间(TTR)和总生存(OS)。
主要发现
- 164例(22%)发生复发。
- 复发接受根治性治疗的比例PET组为48%(42/87),CT组为48%(37/77),两组相同(p=0.98)。
- 经计划随访检出复发的比例PET组为90%,高于CT组77%(p=0.02)。
- TTR两组无显著差异(HR 1.12,95%CI 0.82-1.52,p=0.48)。
- OS两组无显著差异(HR 0.97,95%CI 0.66-1.43,p=0.89)。
临床怎么用
- 作者结论指出,这些发现不支持在该患者人群常规使用[18F]FDG PET/CT进行治疗后监测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Post-treatment surveillance is recommended for NSCLC owing to a high risk of recurrence, but evidence on the optimal surveillance method is lacking. This trial evaluates fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT) versus contrast-enhanced CT (ceCT) for surveillance in patients with NSCLC. METHODS: In this multicenter, randomized controlled trial (SUPE_R, ClinicalTrials.gov NCT03740126), patients with stage IA-to-IIIC NSCLC were randomized one-to-one to standard surveillance (ceCT) or surveillance with [18F]FDG PET/CT after completion of curative treatment. The primary outcome was the proportion of recurrences treated with curative intent. Secondary outcomes included time to recurrence (TTR) and overall survival (OS). RESULTS: Between February 2019 and February 2022, 750 patients were randomized to PET/CT (n = 373) or CT (n = 377). Recurrences occurred in 164 patients (22%). The proportion of recurrences treated with curative intent was identical in the PET group (42/87) and CT group (37/77), both 48% (p = 0.98). More recurrences were detected through scheduled follow-up in the PET group (90%) than in the CT group (77%; p = 0.02). There were no significant differences in TTR (hazard ratio 1.12, 95% confidence interval 0.82-1.52, p = 0.48) or OS (hazard ratio 0.97, 95% confidence interval 0.66-1.43, p = 0.89) between groups. CONCLUSIONS: Surveillance with [18F]FDG PET/CT did not improve rates of curatively treated recurrences, TTR, or OS compared with ceCT in patients with NSCLC after curative treatment. These findings do not support the routine use of [18F]FDG PET/CT for post-treatment surveillance in this patient population.
引用
- Guldbrandsen KF, Bloch M, Skougaard K, et al. Surveillance With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of Patients With Stage I-to-III Lung Cancer After Completion of Curative treatment (SUPE_R): A Randomized Controlled Trial. J Thorac Oncol. 2025. PMID: 40258572. doi:10.1016/j.jtho.2025.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。